Genetic animal models: Focus on schizophrenia

Trends in Neurosciences

Volumn 24, Issue 9, 2001, Pages 527-533

  Gainetdinov, Raul R ^a   Mohn, Amy R ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; AMPHETAMINE; CLOZAPINE; DEXTRORPHAN; DIZOCILPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; GLUTAMIC ACID; HALOPERIDOL; KAINIC ACID RECEPTOR; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NISOXETINE; PHENCYCLIDINE; RACLOPRIDE; RISPERIDONE; SEROTONIN;

BEHAVIOR DISORDER; DISEASE ASSOCIATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; GENETIC MODEL; HUMAN; HYPOTHESIS; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SYMPTOM; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; SCHIZOPHRENIA;

EID: 0035451642     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(00)01886-5     Document Type: Review

References (80)

1. Catching up on schizophrenia. Natural history and neurobiology
2. Interaction between monoamines, glutamate, and GABA in schizophrenia: New evidence
3. To model a psychiatric disorder in animals: Schizophrenia as a reality test
4. Dissection of behavior and psychiatric disorders using the mouse as a model
5. Pharmacological models of psychoses
6. Animal models for human PFC-related disorders
7. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
8. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
9. Animal models of human genetic diseases
10. The glutamatergic dysfunction hypothesis for schizophrenia
11. Schizophrenia and glutamatergic transmission
12. Dopamine receptors and the dopamine hypothesis of schizophrenia
13. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
14. Amphetamine: Effects on catecholamine systems and behavior
15. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport
16. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter
17. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine
18. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity
19. Amphetamine psychosis: I. Description of the individuals and process
20. Amphetamine psychosis: A 'model' schizophrenia mediated by catecholamines
21. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys
22. Stimulant-induced psychosis: An evaluation of animal methods
23. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia
24. Amphetamine psychosis and schizophrenia: A dual model
25. Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats
26. Glutamate in CNS disorders as a target for drug development: An update
27. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders
28. Recent advances in the phencyclidine model of schizophrenia
29. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia
30. Rodent data and general hypothesis: Antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone
31. The role of serotonin in antipsychotic drug action
32. PCP site 2: A high affinity MK-801-insensitive phencyclidine binding site
33. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine
34. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
35. Profound neuronal plasticity in response to inactivation of the dopamine transporter
36. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis
37. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter
38. Loss of autoreceptor functions in mice lacking the dopamine transporter
39. Functional hyperdopaminergia in dopamine transporter knock-out mice
40. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter
41. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice
42. Dopaminergic role in stimulant-induced wakefulness
43. Cocaine self-administration in dopamine transporter knockout mice
44. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: Differential effects of D1 and D2 receptor antagonists
45. No evidence for linkage or association between the dopamine transporter gene and schizophrenia in a French population
46. Genotypic association between dopamine transporter gene polymorphisms and schizophrenia
47. Association of attention-deficit disorder and the dopamine transporter gene
48. An animal model of attention deficit hyperactivity disorder
49. New insights into dopaminergic receptor function using antisense and genetically altered animals
50. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors
51. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations
52. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice
53. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors
54. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses
55. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: Paradoxical elevation of grooming syntax
56. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine
57. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli
58. Altered striatal function in a mutant mouse lacking D1A dopamine receptors
59. Behavioural assessment of mice lacking D1A dopamine receptors
60. Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors
61. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic
62. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists
63. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior
64. Monoamine oxidase: From genes to behavior
65. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice
66. Spatial learning deficit in dopamine D(1) receptor knockout mice
67. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice
68. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death
69. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice
70. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
71. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit
72. Long-trace interval eyeblink conditioning is impaired in mutant mice lacking the NMDA receptor subunit epsilon1
73. The molecular biology of serotonin receptors: Therapeutic implications for the interface of mood and psychosis
74. Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission
75. Cholinergic aspects of schizophrenia
76. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia
77. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade
78. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1
79. NCAM-180 knockout mice display increased lateral ventricle size and reduced prepulse inhibition of startle